Premium
Retinol binding protein‐4 circulating levels were higher in nonalcoholic fatty liver disease vs. histologically normal liver from morbidly obese women
Author(s) -
Terra Ximena,
Auguet Teresa,
Broch Montserrat,
Sabench Fàtima,
Hernández Mercè,
Pastor Rosa M.,
Quesada Isabel M.,
Luna Anna,
Aguilar Carmen,
del Castillo Daniel,
Richart Cristóbal
Publication year - 2013
Publication title -
obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.438
H-Index - 199
eISSN - 1930-739X
pISSN - 1930-7381
DOI - 10.1002/oby.20233
Subject(s) - adipokine , nonalcoholic fatty liver disease , adipose tissue , retinol binding protein 4 , medicine , adiponectin , endocrinology , fatty liver , steatosis , liver disease , morbidly obese , obesity , leptin , insulin resistance , disease , weight loss
Objective: We aimed to analyze the retinol binding protein‐4 (RBP4) messenger RNA (mRNA) expression profiles in adipose tissues and liver of morbidly obese (MO) women with or without nonalcoholic fatty liver disease (NAFLD), and to study the relationships with other pro‐ and anti‐inflammatory adipokines in vivo and in vitro.Design and Methods: We performed a cross‐sectional analysis of subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT) and liver samples from four lean and 45 MO women with or without NAFLD by enzyme‐linked immunosorbent assay and real‐time reverse transcription‐PCR. We also studied RBP4 expression in HepG2 hepatocytes under various inflammatory stimuli. Results: Circulating RBP4 levels were higher in MO women, and specifically, in MO subjects with NAFLD compared with normal liver controls (lean and MO). RBP4 liver expression was higher in nonalcoholic steatohepatitis (NASH)‐moderate/severe than in NASHmild. Overall RBP4 gene expression was higher in liver than in adipose tissues. Among them, the higher expression corresponded to SAT. VAT expression was lower in the MO cohort. In HepG2, RBP4 mRNA expression was reduced by tumor necrosis factor (TNF)‐α and increased by adiponectin treatment. Conclusions: The results obtained in MO women with NAFLD, brings up the use of RBP4 and other adipokines as a panel of noninvasive molecular biomarkers when NAFLD is suspected. Further studies are needed with other obesity groups.